Lidoderm Generic Antitrust Settlement
Closed Settlement Statement:
According to court documents, the claim submission deadline has passed. Please contact the claims administrator if you have any questions.
Three settlements resolve class actions against a number of companies:
- Endo Pharmaceuticals Inc. (“Endo”)
- Teikoku Pharma USA, Inc., Teikoku Seiyaku Co., Ltd. (together “Teikoku”)
- Actavis, Inc., Watson Laboratories, Inc., Actavis plc, Anda Inc., Anda Pharmaceuticals, Inc. and Valmed Pharmaceuticals, Inc. (together “Watson”)
The complaint alleged that as part of a 2012 settlement of a patent infringement case, Endo and Teikoku paid Watson to delay introduction of a generic version of Lidoderm. Plaintiffs in the case include both consumers and third-party payors who claim that the anticompetitive agreement between the companies violated antitrust laws and kept prices of Lidoderm artificially high.
Thursday, August 23, 2012 to Friday, August 1, 2014
Final Approval Hearing:
Wednesday, September 12, 2018